Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.99 0.04 (0.5%) Market Cap: 2.24 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 40/100

Iovance Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 07:00PM GMT
Release Date Price: $29.62 (-5.67%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have Iovance Biotherapeutics with us. We have Maria Fardis, President and CEO here. And with that, Maria, thanks for joining us.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And to start, adoptive cell therapy is a rapidly expanding field. And can you just talk about your choice of using TILs to target cancer? And how this is differentiated, I guess, from the other approaches that we're seeing with CAR Ts, TCRs and some of the others? And are there particularly -- particular indications here that you see as more appropriate to be addressed with TILs? Or do you see -- and where do you see widespread potential of this modality? Lots of questions in one.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Thank you, Salveen. Can I confirm you can

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot